Coya Therapeutics COYA 深 滬
交易中 09-24 11:33:32 美东时间
4.955
-0.085
-1.69%
華盛通- 最 高5.02
- 今 開5.02
- 成交量 2.00万股
- 最 低 4.94
- 昨 收 5.04
- 總市值 1.16亿
- 52周最高 7.75
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 3.7101
- 委 比 -90.53%
- 總股本 2345.78万
- 歷史最高 10.6899
- 量 比 0.29
- 振 幅 1.59%
- 歷史最低 3.21
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.
09-16 00:11
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027 Additional participants continue to roll over into the active extension arm of the trial COYA 302 has received FDA Fast Track designation for the treatment of ALS
09-15 20:03
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.
08-25 01:07
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $243.745 tho...
08-11 20:11
美股大行评级 | Ciena、Rubrik获多家大行上调目标价；库珀医疗、Guidewire软件、露露乐蒙等遭多家大行下调目标价
今日重点评级关注：瑞银：维持DraftKings"买入"评级，目标价从43美元升至49美元；Needham：维持Planet Labs"买入"评级，目标价从40美元升至53美元
06-08 11:33
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.
06-05 18:29
Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is a 27.27 percent increase over losses of $(0.44) per share from
05-12 19:50
Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
05-12 19:33
